
Keywords: RA; rheumatoid arthritis; TCZ; tocilizumab; TOFA; tofacitinib citrate; MTX; methotrexate; DMARD; disease-modifying antirheumatic drug; bDMARD; biologic disease-modifying antirheumatic drug; nbDMARD; non-biologic disease-modifying antirheumatic drug; obDMA